ロード中...
Clinical Overview of MDM2/X-Targeted Therapies
MDM2 and MDMX are the primary negative regulators of p53, which under normal conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid degradation and inhibiting its transcriptional activity. Both MDM2 and MDMX function as powerful oncogenes and are commonly ove...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4728205/ https://ncbi.nlm.nih.gov/pubmed/26858935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2016.00007 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|